APA (7th ed.) Citation

P, Y., LP, P., AC, H., AK, L., D, Y., SE, B., . . . AV, C. (2024). Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: A phase 1/2, multicentre, open-label, unilateral dose escalation study. Lancet (London, England), 404(10456), 962. https://doi.org/10.1016/S0140-6736(24)01447-8

Chicago Style (17th ed.) Citation

P, Yang, et al. "Safety and Efficacy of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D: A Phase 1/2, Multicentre, Open-label, Unilateral Dose Escalation Study." Lancet (London, England) 404, no. 10456 (2024): 962. https://doi.org/10.1016/S0140-6736(24)01447-8.

MLA (9th ed.) Citation

P, Yang, et al. "Safety and Efficacy of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D: A Phase 1/2, Multicentre, Open-label, Unilateral Dose Escalation Study." Lancet (London, England), vol. 404, no. 10456, 2024, p. 962, https://doi.org/10.1016/S0140-6736(24)01447-8.